S

tung by reports of backpedaling on a pledge to limit drug price hikes, AbbVie (ABBV) insisted on Tuesday that it will stick to just one, single-digit price increase next year.

The statement came a day after news reports — including ours — indicated the drug maker would abandon its commitment to keep all price increases below 10 percent and raise prices only once a year, although AbbVie maintained its pledge referred only to this year. The original source for the stories was a report from a Wall Street securities analyst, who summarized AbbVie remarks following a meeting with company management last week.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy